Bristol-Myers Squibb (NYSE:BMY) Given Average Rating of "Hold" by Analysts

Shares of Bristol-Myers Squibb (NYSE:BMY - Get Free Report) have earned an average recommendation of "Hold" from the twenty-two analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $58.00.

BMY has been the subject of several research analyst reports. Jefferies Financial Group dropped their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th.

Bristol-Myers Squibb Price Performance

NYSE BMY traded up $1.60 during midday trading on Tuesday, hitting $45.72. The company had a trading volume of 27,423,080 shares, compared to its average volume of 13,257,092. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market capitalization of $93.04 billion, a PE ratio of -10.34, a P/E/G ratio of 2.07 and a beta of 0.39. The firm has a 50-day moving average price of $53.69 and a 200-day moving average price of $56.06.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.40) EPS. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.42%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.09% of the company's stock.

Hedge Funds Weigh In On Bristol-Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $25,000. Park Square Financial Group LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $26,000. Fairway Wealth LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $28,000. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Finally, Global Wealth Strategies & Associates raised its stake in Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.